ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial

ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial

Abstract Background The CAO/ARO/AIO-94 demonstrated that neoadjuvant chemoradiotherapy (CRT) could decrease the rate of local recurrence rather than distal metastases in advanced rectal cancer. Adjuvant chemotherapy (ACT) can eliminate micrometastasis, and render a better prognosis to rectal cancer....

Full description

Bibliographic Details
Main Authors: Qingguo Li, Dakui Luo, Ji Zhu, Lifeng Yang, Qi Liu, Yanlei Ma, Lei Liang, Sanjun Cai, Zhen Zhang, Xinxiang Li, ACRNaCT study group
Format: Article
Language:English
Published: BMC 2019-11-01
Series:BMC Cancer
Subjects:
Neoadjuvant chemoradiotherapy
Adjuvant chemotherapy
Locally advanced rectal cancer
Yield pathological stage
Online Access:http://link.springer.com/article/10.1186/s12885-019-6289-6

Internet

http://link.springer.com/article/10.1186/s12885-019-6289-6

Similar Items